Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually
As the U.S. makes headway in its coronavirus vaccination campaign, Emergent BioSolutions CEO Bob Kramer appeared on CNBC Wednesday to explain his company’s role in manufacturing doses.
The Gaithersburg, Maryland-based contractor last year landed a multi-year deal to be the domestic producer of the Covid-19 vaccine from Johnson & Johnson, whose single-dose shot was cleared for use in the U.S. over the weekend. It also has a multi-year contract production contract for a vaccine developed by a British-Swedish biopharmaceutical company, AstraZeneca.
“We’re now at the point where we have this infrastructure in place and we’re producing on a daily basis, 24/7, both AZ and the J&J products,” Kramer told Jim Cramer in a “Mad Money” interview. “We are operating at a level where our capacity is well in access of 1 billion doses annually for those products.”
Emergent BioSolutions got started …continued .
[Source: CNBC News]